Stock listing

Frankfurt:M55 MacroGenics, Inc. Aktie

German listing (Frankfurt) of MacroGenics, Inc. · home listing NASDAQ:MGNX

Follow MacroGenics, Inc. into a list and get an email when it puts out news.

Share price · FWB:M55

€1.79 EUR 0.00 (0.0%)

Close on Nov 20, 2026

Past year +75.4% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
€1.79 – €1.79 EURNov 20, 2026
Market cap
€114.0M EURAt the close on Nov 20, 2026 · price × 63.70M shares outstanding
52-week range
€1.14 – €4.19 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€2,072 EURMedian day 0 shares · 45 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
MacroGenics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MGNX · Home$1.96 USD-0.01 (-0.5%)1,524,423$1.96$2.08$1.902$1.97Close on Nov 20, 2026
Frankfurt:M55€1.79 EUR0.00 (0.0%)—€1.79€1.79€1.79€1.79Close on Nov 20, 2026
Stuttgart:M55€1.79 EUR-0.01 (-0.6%)—€1.78€1.82€1.73€1.80Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:M55 · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€2.143+0.09+4.4%€1.979€2.152€1.9790
€2.053-0.036-1.7%€2.053€2.053€2.05340
€2.089-0.035-1.6%€2.089€2.089€2.08940
€2.124-0.012-0.6%€2.124€2.124€2.1240
€2.136+0.047+2.2%€2.136€2.136€2.1360
€2.089-0.095-4.3%€2.089€2.089€2.0890
€2.1840.000.0%€2.184€2.184€2.18414,110
€2.184+0.228+11.7%€2.184€2.184€2.1846,000
€1.956-0.008-0.4%€1.956€1.956€1.9560
€1.964-1.235-38.6%€1.964€1.964€1.9641,098
€3.199+0.042+1.3%€3.199€3.199€3.1990
€3.157+0.092+3.0%€3.157€3.157€3.1570
€3.065+0.106+3.6%€3.065€3.065€3.0650
€2.959+0.101+3.5%€2.959€2.959€2.9590
€2.858-0.127-4.3%€2.858€2.858€2.8580
€2.985+0.034+1.2%€2.985€2.985€2.9850
€2.951-0.075-2.5%€2.951€2.951€2.9510
€3.026-0.254-7.7%€3.026€3.026€3.0260
€3.28-0.029-0.9%€3.28€3.28€3.28500
€3.309+0.203+6.5%€3.309€3.309€3.3090
€3.106-0.036-1.1%€3.106€3.106€3.10638
€3.142-0.079-2.5%€3.141€3.142€3.14138
€3.221-0.098-3.0%€3.221€3.221€3.2210
€3.319+0.186+5.9%€3.319€3.319€3.3190
€3.133-0.033-1.0%€3.133€3.133€3.1330
€3.166-0.20-5.9%€3.166€3.166€3.1660
€3.366+0.079+2.4%€3.366€3.366€3.3660
€3.287-0.26-7.3%€3.287€3.287€3.2870
€3.547+0.292+9.0%€3.547€3.547€3.5470
€3.255-0.083-2.5%€3.255€3.255€3.2550
€3.338+0.019+0.6%€3.289€3.365€3.269200
€3.319-0.249-7.0%€3.319€3.319€3.3190
€3.568-0.018-0.5%€3.568€3.568€3.5680
€3.586-0.071-1.9%€3.586€3.586€3.5860
€3.657+0.094+2.6%€3.564€3.661€3.54714,500
€3.563+0.04+1.1%€3.563€3.563€3.5630
€3.523+0.081+2.4%€3.523€3.523€3.5230
€3.442-0.151-4.2%€3.442€3.442€3.4420
€3.593+0.177+5.2%€3.593€3.593€3.5930
€3.416+0.028+0.8%€3.416€3.416€3.4160
€3.388-0.107-3.1%€3.388€3.388€3.3882,292
€3.495-0.162-4.4%€3.495€3.495€3.4950
€3.657-0.063-1.7%€3.657€3.657€3.6570
€3.72-0.034-0.9%€3.72€3.72€3.720
€3.754+0.125+3.4%€3.754€3.754€3.7540
€3.629-0.058-1.6%€3.629€3.629€3.6290
€3.687+0.249+7.2%€3.687€3.687€3.6870
€3.438+0.021+0.6%€3.438€3.438€3.4380
€3.417-0.117-3.3%€3.417€3.417€3.4170
€3.534+0.083+2.4%€3.534€3.534€3.5340
€3.451+0.029+0.8%€3.451€3.451€3.4510
€3.422-0.146-4.1%€3.422€3.422€3.4220
€3.568+0.155+4.5%€3.568€3.568€3.5680
€3.413-0.066-1.9%€3.413€3.413€3.4130
€3.479+0.075+2.2%€3.479€3.479€3.4790
€3.404-0.144-4.1%€3.404€3.404€3.4042,502
€3.548+0.072+2.1%€3.548€3.548€3.5480
Ticker
Frankfurt:M55
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All MacroGenics, Inc. news

MacroGenics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 133 in all · newest Nov 12, 2026 · oldest 2019
Calls
16 calls with a replay · 16 with a transcript · latest Mar 20, 2025
Decks
9 decks · latest Nov 13, 2026

Where MacroGenics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MGNX · Home listingNASDAQUnited StatesUSD
gettex:M55gettexGermanyEUR
BOATS:MGNXBOATSUnited StatesUSD
LS Exchange:A1W6NDLS ExchangeGermanyEUR
Lang & Schwarz:A1W6NDLang & SchwarzGermanyEUR
Tradegate:M55TradegateGermanyEUR
BX Swiss:M55BX SwissSwitzerlandCHF
Dusseldorf:M55DusseldorfGermanyEUR
Frankfurt:M55 · This pageFrankfurtGermanyEUR
Hamburg:M55HamburgGermanyEUR
Stuttgart:M55StuttgartGermanyEUR

Valuation

EV/sales −0.9× against a median of 40.1×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$127.6M USD
P/E
Loss
EV/sales
−0.9×
EV/EBITDA
Negative EBITDA
Price/book
5.0×
Gross margin
3.2%
Operating margin
−43.7%
Net margin
−34.6%
Debt to equity
1.4×
Beta vs S&P 500
0.83

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
MacroGenics, Inc. · NASDAQ:MGNXUS$125.3M−US$127.6Mn/a−0.9×n/a5.0×−34.6%1.4×0.83
Sionna Therapeutics, Inc. · NASDAQ:SIONUS$127.8M−US$89.05Mn/an/an/a0.5×n/a0.0×1.51
Yoda Pharmaceuticals Inc. · TPEX:7829US$127.1MUS$94.37Mn/an/an/a3.9×n/a0.0×n/a
IntoCell, Inc. · KRX:287840US$126.6MUS$108.8Mn/a45.9×n/a8.7×−295.9%0.0×n/a
UnicoCell Biomed Co., Ltd. · TWSE:6794US$126.3MUS$106.5Mn/a117×n/a5.1×−381.5%0.1×n/a
PolyPid Ltd. · NASDAQ:PYPDUS$124.3MUS$119.3Mn/an/an/a23.1×n/a0.3×0.93
Compass Therapeutics, Inc. · NASDAQ:CMPXUS$123.9M−US$29.89Mn/an/an/a0.9×n/a0.1×1.22
Humacyte, Inc. · NASDAQ:HUMAUS$123.7MUS$96.01Mn/a40.1×n/a6.8×n/a2.0×2.56
Biomm SA · BMFBOVESPA:BIOM3US$122.6MUS$136.5M18.4×2.1×12.3×2.2×10.3%0.3×n/a
Invivyd, Inc. · NASDAQ:IVVDUS$122.0MUS$3.86Mn/a0.1×n/a0.8×−214.8%0.1×2.06
Satellos Bioscience Inc · TSX:MSCLUS$121.9MUS$69.23Mn/an/an/a2.5×n/a0.0×0.49
Median of the othersUS$124.1MUS$95.19M18.4×40.1×12.3×3.2×−255.4%0.1×1.37

Forecasts

2 strong buy · 1 buy · 4 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
8.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.47 · 1 analyst
Revenue, year to Dec 2026
91.27M · 3 analysts

Team and board

Officers

OfficerRole
Jim KarrelsSenior Vice President, CFO

Board

DirectorRole
Meenu Chhabra KarsonDirector

Events

Calls

CallWhenStatus
MacroGenics (NASDAQ:MGNX) Q4 2024 Earnings CallThu, Mar 20, 2025 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q3 2024 Earnings CallTue, Nov 05, 2024 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q1 2024 Earnings CallThu, May 09, 2024 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q4 2023 Earnings CallThu, Mar 07, 2024 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q3 2023 Earnings CallMon, Nov 06, 2023 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q2 2023 Earnings CallWed, Aug 09, 2023 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q1 2023 Earnings CallTue, May 09, 2023 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q4 2022 Earnings CallWed, Mar 15, 2023 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q3 2022 Earnings CallThu, Nov 03, 2022 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q2 2022 Earnings CallMon, Aug 08, 2022 · 4:30 PM ETReplay
All 16 calls
CallWhenStatus
MacroGenics (NASDAQ:MGNX) Q1 2022 Earnings CallTue, May 03, 2022 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q4 2021 Earnings CallThu, Feb 24, 2022 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q3 2021 Earnings CallTue, Nov 02, 2021 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q2 2021 Earnings CallThu, Jul 29, 2021 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q1 2021 Earnings CallThu, Apr 29, 2021 · 4:30 PM ETReplay
MacroGenics (NASDAQ:MGNX) Q3 2020 Earnings CallWed, Nov 04, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−3.9%
Q2 2026Aug 13, 2026 · After close+3.4%
Q1 2026May 13, 2026 · After close+20.6%
Q4 2025Feb 19, 20260.0%
Q3 2025Nov 12, 2025 · After close+8.8%
Q2 2025Aug 14, 2025 · After close−2.5%
Q1 2025May 13, 2025 · After close+0.7%
Q4 2024Mar 5, 2025 · Before open+2.6%
Q3 2024Nov 5, 2024 · After close+11.1%
Q2 2024Aug 6, 2024 · After close−7.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−77.4%
Q4 2023Mar 7, 2024 · After close−15.0%
Q3 2023Nov 6, 2023 · After close+17.1%
Q2 2023Aug 9, 2023 · After close+24.3%
Q1 2023May 9, 2023 · After close+0.4%
Q4 2022Mar 15, 2023 · After close+10.3%
Q3 2022Nov 3, 2022 · After close+22.3%
Q2 2022Aug 8, 2022 · After close+12.1%
Q1 2022May 3, 2022 · After close−16.9%
Q4 2021Feb 24, 2022 · After close−7.8%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (November 2026)Corporate update28 slidesNov 13, 2026
Technical Presentation (October 2026)Technical24 slidesOct 23, 2026
Investor Presentation (August 2026)Investor deck21 slidesAug 13, 2026
Post-ESMO Conference Call (September 2024)Conference23 slidesSep 16, 2024
Technical Presentation (May 2024)Technical17 slidesMay 9, 2024
Technical Presentation (June 2021)Technical36 slidesJun 4, 2021
Investor Presentation (December 2020)Investor deck14 slidesDec 17, 2020
ASCO 2020Conference18 slidesMay 29, 2020
ESMO 2020Conference13 slides2020

Open Decks

IPO

Final prospectus filed on Oct 11, 2013.

Shares offered
5,000,000 shares of common stock
Underwriters' option
Up to 750,000 more shares
Underwriters
BofA Merrill Lynch, Leerink Swann, Stifel, Lazard Capital Markets, Wedbush PacGrow Life Sciences · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 2, 2013
Filed publiclySep 4, 2013
Amended 4 timesNewest Oct 9, 2013
Shares registered with an exchangeOct 7, 2013
Declared effective by the SECOct 9, 2013
Final prospectus, with the priceOct 11, 2013

Open IPO · From the cover of the amended prospectus (S-1/A) filed Oct 9, 2013

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue149.5M150.0M58.7M151.9M77.4M104.9M64.2M60.1M157.7M91.9M
Cost of revenue0847.0K619.0K3.35M2.65M00190.8M147.2M122.1M
Gross profit106.3M136.0M49.0M144.6M73.0M97.8M62.0M60.1M155.5M86.6M
Research and development147.2M177.2M166.6M207.0M214.6M193.2M195.3M190.8M147.2M122.1M
Selling, general and administrative39.2M71.0M52.2M58.9M63.0M42.7M46.1M40.5M32.7M29.8M
Operating income-72.8M-110.6M-168.2M-121.4M-202.8M-131.1M-177.2M-171.2M-22.1M-60.0M
Depreciation and amortization7.17M7.54M9.64M11.9M11.3M12.0M12.3M9.16M7.23M7.61M
EBITDA-65.7M-103.0M-158.6M-109.6M-191.5M-119.1M-164.9M-162.0M-14.9M-52.4M
Interest expense8.51M1.11M1.43M0000000
Income before tax-75.3M-66.0M-9.06M-119.8M-202.1M-129.7M-151.8M-171.5M-19.6M-58.5M
Income tax-672.0K944.0K00000000
Net income-74.6M-67.0M-9.06M-119.8M-202.1M-129.7M-151.8M-171.5M-19.6M-58.5M
Earnings per share, basic-1.18-1.07-0.15-1.95-3.37-2.47-3.10-4.05-0.54-1.69
Earnings per share, diluted-1.18-1.07-0.15-1.95-3.37-2.47-0.54-1.69

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents57.2M182.8M101.0M108.9M123.5M181.1M126.5M220.1M211.7M84.1M
Short-term investments132.7M18.8M128.8M45.5M120.1M91.4M89.3M12.7M93.4M192.9M
Receivables427.0K4.31M10.4M56.2M10.4M23.1M12.7M29.6M13.6M2.76M
Inventory7.91M01.22M1.45M4.39M010-7.99M
Current assets219.9M217.5M251.3M222.2M279.6M312.6M239.8M269.1M322.3M283.9M
Property, plant and equipment2.10M18.1M21.8M29.6M37.7M42.2M48.2M56.7M50.0M18.0M
Goodwill00
Total assets256.8M261.7M298.4M280.5M335.2M378.7M312.5M332.1M373.9M311.3M
Accounts payable3.26M5.01M6.44M4.90M15.5M8.03M4.31M4.00M2.45M4.00M
Current liabilities43.1M55.5M56.1M48.6M74.6M50.7M45.2M59.9M49.8M27.3M
Long-term debt00
Total debt106.8M37.5M34.0M34.8M25.5M29.2M30.6M298.0K1.89M
Total liabilities201.3M145.6M145.8M138.5M95.6M82.9M81.9M89.3M74.6M42.5M
Shareholders' equity55.6M116.1M152.6M142.0M239.6M295.9M230.6M242.9M299.2M268.8M
Shares outstanding63.3M62.8M62.1M61.7M61.3M56.2M49.0M42.4M36.9M34.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-81.0M-68.4M-78.2M-87.0M-143.8M-111.9M-134.3M-153.2M14.4M-43.7M
Capital spending-1.91M-3.71M-1.76M-3.62M-6.20M-5.91M-4.29M-25.0M-29.4M-11.4M
Free cash flow-83.0M-72.1M-80.0M-90.6M-150.0M-117.8M-138.6M-178.2M-15.0M-55.1M
Cash from investing-114.1M149.3M-80.1M70.7M-36.6M-7.79M-79.4M56.6M77.9M-70.2M
Cash from financing69.5M960.0K150.4M1.66M122.8M174.3M120.0M105.0M35.3M1.85M
Dividends paid00
Share buybacks-306.0K1.08M117.8M-2.01M0-260.0K-40.0K-39.0K
Change in cash-125.6M81.9M-7.93M-14.6M-57.7M54.7M-93.7M8.40M127.6M-112.1M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 13, 2026Current reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 3, 2026Insider tradeSEC
8-K · Current reportNov 3, 2026Management or board changeSEC
8-K · Current reportOct 23, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleOct 22, 2026Other filingsSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
144 · Notice of proposed saleSep 21, 2026Other filingsSEC
S-8 · Registration statement for employee plansSep 3, 2026Offer documentSEC
8-K/A · Current report, amendedSep 3, 2026Current reportSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 13, 2026ResultsSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 3, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2026Big-stake noticeSEC
8-K · Current reportJul 23, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 20, 2026Big-stake noticeSEC
144 · Notice of proposed saleJul 13, 2026Other filingsSEC
8-K · Current reportJul 8, 2026Management or board changeSEC
8-K · Current reportJul 7, 2026Acquisition or disposalSEC
SCHEDULE 13G · Big-stake noticeJun 5, 2026Big-stake noticeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
8-K · Current reportMay 20, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2026Big-stake noticeSEC
8-K · Current reportMay 13, 2026ResultsSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026Material contractSEC
8-K · Current reportMay 4, 2026Material contractSEC
DEFA14A · Additional proxy materialApr 22, 2026Meeting noticeSEC
8-K · Current reportApr 8, 2026Current reportSEC
DEFA14A · Additional proxy materialApr 8, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 8, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
8-K · Current reportMar 9, 2026ResultsSEC
10-K · Annual reportMar 9, 2026Annual reportSEC
8-K · Current reportMar 2, 2026Current reportSEC
8-K · Current reportFeb 23, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 6, 2026Big-stake noticeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
8-K · Current reportNov 20, 2025Management or board changeSEC
8-K · Current reportNov 12, 2025ResultsSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
4 · Change in ownershipAug 21, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 14, 2025Offer documentSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 13, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 17, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 13, 2025Big-stake noticeSEC
8-K · Current reportJun 10, 2025Material contractSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
8-K · Current reportMay 22, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 13, 2025ResultsSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 11, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 11, 2025Meeting noticeSEC
8-K · Current reportMar 20, 2025ResultsSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportFeb 26, 2025Management or board changeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2025Big-stake noticeSEC
3 · Initial statement of ownershipJan 13, 2025Insider tradeSEC
UPLOAD · Letter from the SECJan 10, 2025Other filingsSEC
CORRESP · Letter to the SECJan 3, 2025Other filingsSEC
UPLOAD · Letter from the SECDec 3, 2024Other filingsSEC
8-K · Current reportNov 21, 2024Management or board changeSEC
SC 13G · Big-stake noticeNov 20, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
8-K · Current reportNov 5, 2024ResultsSEC
10-Q · Quarterly reportNov 5, 2024Quarterly reportSEC
8-K · Current reportOct 30, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedOct 22, 2024Big-stake noticeSEC
4 · Change in ownershipOct 9, 2024Insider tradeSEC
4 · Change in ownershipSep 25, 2024Insider tradeSEC
8-K · Current reportSep 16, 2024Current reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportJul 30, 2024Current reportSEC
8-K · Current reportJul 30, 2024Current reportSEC
SC 13G · Big-stake noticeJun 4, 2024Big-stake noticeSEC
4/A · Change in ownership, amendedMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
8-K · Current reportMay 23, 2024Meeting outcomeSEC
S-8 · Registration statement for employee plansMay 23, 2024Offer documentSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
SC 13G · Big-stake noticeMay 21, 2024Big-stake noticeSEC
8-K · Current reportMay 9, 2024ResultsSEC
8-K · Current reportMay 9, 2024Current reportSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
4 · Change in ownershipApr 8, 2024Insider tradeSEC
ARS · Annual report to shareholdersApr 8, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 8, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 8, 2024Meeting noticeSEC
144 · Notice of proposed saleApr 4, 2024Other filingsSEC
8-K · Current reportApr 3, 2024Current reportSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
8-K · Current reportMar 7, 2024ResultsSEC
10-K · Annual reportMar 7, 2024Annual reportSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
144 · Notice of proposed saleMar 6, 2024Other filingsSEC
144 · Notice of proposed saleMar 4, 2024Other filingsSEC
144 · Notice of proposed saleMar 4, 2024Other filingsSEC
144 · Notice of proposed saleMar 4, 2024Other filingsSEC
4 · Change in ownershipFeb 28, 2024Insider tradeSEC
4 · Change in ownershipFeb 26, 2024Insider tradeSEC
4 · Change in ownershipFeb 26, 2024Insider tradeSEC
144 · Notice of proposed saleFeb 26, 2024Other filingsSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC

This page holds 200 of 948 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from MacroGenics, Inc.’s releases · as of Nov 6, 2026

Common shares
63,908,946
Fully diluted
63,908,946

Fully diluted

LineSharesAs of
Common shares63,908,946Nov 6, 2026

Share count over time

CountShares
Nov 6, 202663,908,946

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock6.15M9.6%US$23.7MSep 30, 2026
Armistice Capital, LLC6M9.4%US$23.2MSep 30, 2026
Vanguard5.21M8.1%US$20.1MSep 30, 2026
Acadian Asset Management LLC2.54M4.0%US$9.81MSep 30, 2026
Two Sigma2.38M3.7%US$9.19MSep 30, 2026
Renaissance Technologies2.18M3.4%US$8.41MSep 30, 2026
Mackenzie2.01M3.2%US$7.77MSep 30, 2026
Ra Capital Management, L.P.1.86M2.9%US$7.2MSep 30, 2026
Geode Capital1.75M2.7%US$6.77MSep 30, 2026
Marshall Wace, LLP1.34M2.1%US$5.19MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Wasatch Advisors LP1.26M2.0%US$4.87MSep 30, 2026
ADAR1 Capital Management, LLC1.23M1.9%US$4.77MSep 30, 2026
Millennium1.2M1.9%US$4.62MSep 30, 2026
State Street1.17M1.8%US$4.51MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.1.08M1.7%US$4.16MSep 30, 2026
D. E. Shaw & Co., Inc.992K1.6%US$3.83MSep 30, 2026
Affinity Asset Advisors, LLC954K1.5%US$3.68MSep 30, 2026
Bank of America892K1.4%US$3.44MSep 30, 2026
Jacobs Levy Equity Management, Inc777K1.2%US$3MSep 30, 2026
Pinnacle Associates LTD648K1.0%US$2.5MSep 30, 2026
Citadel585K0.92%US$2.26MSep 30, 2026
Northern Trust524K0.82%US$2.02MSep 30, 2026
Goldman Sachs473K0.74%US$1.83MSep 30, 2026
Nomura420K0.66%US$1.62MSep 30, 2026
Fidelity419K0.66%US$1.62MSep 30, 2026
Diadema Partners LP262K0.41%US$1.01MSep 30, 2026
Panagora Asset Management Inc250K0.39%US$966KSep 30, 2026
Man Group plc237K0.37%US$917KSep 30, 2026
Nuveen195K0.30%US$751KSep 30, 2026
Schwab193K0.30%US$744KSep 30, 2026
Strs Ohio178K0.28%US$689KSep 30, 2026
LPL Financial LLC168K0.26%US$648KSep 30, 2026
XTX Topco Ltd149K0.23%US$574KSep 30, 2026
Russell Investments Group, Ltd.144K0.23%US$557KSep 30, 2026
Sei Investments Co138K0.22%US$532KSep 30, 2026
BNY135K0.21%US$521KSep 30, 2026
Susquehanna134K0.21%US$517KSep 30, 2026
Informed Momentum Co LLC124K0.19%US$479KSep 30, 2026
Morgan Stanley119K0.19%US$458KSep 30, 2026
Jump Financial, LLC110K0.17%US$424KSep 30, 2026
Amundi103K0.16%US$399KSep 30, 2026
Point72 Asset Management, L.P.101K0.16%US$389KSep 30, 2026
Tudor Investment Corp Et Al90,6760.14%US$350KSep 30, 2026
Invesco83,9010.13%US$324KSep 30, 2026
Alps Advisors Inc83,7890.13%US$323KSep 30, 2026
UBS82,2640.13%US$318KSep 30, 2026
Caption Management, LLC77,7150.12%US$300KSep 30, 2026
Ikarian Capital, LLC74,8930.12%US$289KSep 30, 2026
Bridgeway Capital Management, LLC72,2760.11%US$279KSep 30, 2026
Empowered Funds, LLC72,2760.11%US$279KSep 30, 2026

This page holds 50 of 124 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.93M3.0%US$8.9MJun 30, 2026
iShares Russell 2000 ETF1.56M2.4%US$7.21MJun 30, 2026
Wasatch Ultra Growth Fund1.12M1.7%US$5.16MJun 30, 2026
Wasatch Micro Cap Fund771K1.2%US$3.56MJun 30, 2026
Fidelity Small Cap Index Fund683K1.1%US$2.52MJul 31, 2026
Vanguard Extended Market Index Fund649K1.0%US$3MJun 30, 2026
Vanguard Strategic Small-Cap Equity Fund551K0.86%US$2.55MJun 30, 2026
iShares Russell 2000 Growth ETF513K0.80%US$2.37MJun 30, 2026
Small Company Growth Portfolio438K0.68%US$2.02MJun 30, 2026
Vanguard Explorer Fund422K0.66%US$1.56MJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Nomura Healthcare Fund420K0.66%US$1.94MJun 30, 2026
Fidelity Extended Market Index Fund303K0.47%US$1.26MMay 31, 2026
iShares Micro-Cap ETF211K0.33%US$976KJun 30, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund178K0.28%US$656KJul 31, 2026
Schwab Small-Cap Index Fund153K0.24%US$563KJul 31, 2026
Vanguard Health Care Index Fund146K0.23%US$609KMay 31, 2026
Master Small Cap Index Series117K0.18%US$542KJun 30, 2026
Fidelity Total Market Index Fund111K0.17%US$463KMay 31, 2026
Wasatch Long/Short Alpha Fund96,0360.15%US$444KJun 30, 2026
Fidelity Series Total Market Index Fund89,0400.14%US$370KMay 31, 2026
Nuveen Small Cap Blend Index Fund83,6330.13%US$309KJul 31, 2026
PACE Small/Medium Co Growth Equity Investments75,4160.12%US$278KJul 31, 2026
Ultra-Small Company Market Fund73,5000.12%US$340KJun 30, 2026
EQ/2000 Managed Volatility Portfolio67,4540.11%US$312KJun 30, 2026
Dimensional U.S. Small Cap ETF65,7030.10%US$242KJul 31, 2026
VIP Disciplined Small Cap Portfolio62,3340.10%US$288KJun 30, 2026
iShares Russell 2000 Value ETF55,8740.09%US$258KJun 30, 2026
Avantis U.S. Small Cap Equity ETF54,5710.09%US$227KMay 31, 2026
Goldman Sachs Small Cap Equity Insights Fund51,5780.08%US$190KJul 31, 2026
Fidelity Small Cap Growth Index Fund51,0560.08%US$236KJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account48,1200.08%US$222KJun 30, 2026
LVIP State Street Small-Cap Index Fund46,1000.07%US$213KJun 30, 2026
U.S. Small Cap Equity Fund45,9050.07%US$169KJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF43,4750.07%US$160KJul 31, 2026
Fidelity Nasdaq Composite Index Fund42,0730.07%US$175KMay 31, 2026
Schwab Total Stock Market Index Fund40,0000.06%US$148KJul 31, 2026
Small Cap Index Fund32,4080.05%US$150KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund32,1840.05%US$149KJun 30, 2026
Vanguard Balanced Index Fund31,7810.05%US$147KJun 30, 2026
Fidelity ZERO Total Market Index Fund30,0030.05%US$111KJul 31, 2026
Global X Russell 2000 ETF29,8810.05%US$110KJul 31, 2026
Goldman Sachs Absolute Return Tracker Fund29,1530.05%US$135KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio21,6000.03%US$99,792Jun 30, 2026
Goldman Sachs Small Cap Growth Insights Fund21,5570.03%US$79,545Jul 31, 2026
MetLife Russell 2000 Index Portfolio21,1730.03%US$97,819Jun 30, 2026
Fidelity ZERO Extended Market Index Fund20,8520.03%US$76,944Jul 31, 2026
Diversified Equity Alpha Master Portfolio20,3340.03%US$93,943Jun 30, 2026
Allspring Disciplined Small Cap Fund18,8630.03%US$87,147Jun 30, 2026
Small-Cap Index Portfolio17,8510.03%US$82,472Jun 30, 2026
U.S. Micro Cap Portfolio15,6240.02%US$57,653Jul 31, 2026

This page holds 50 of 110 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Peters Jeffrey Stuart
Officer: Senior VP, GC, and Secretary
Sale31,105USD 4.15US$129KAug 19, 2026

Big stakes

StakeStakeSharesDateFiling
Armistice Capital, LLC9.42%6MSep 30, 2026Schedule 13G
BlackRock, Inc.7.10%4.5MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Arnold L Oronsky
Other companies: PMV Pharmaceuticals, Inc. (Director · Sep 24, 2020 – Sep 25, 2020 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 1, 2020 · Past); Tesaro Inc (Director · Jun 27, 2012 – Aug 7, 2018 · Past); Anesiva Inc (Director · Jun 22, 2006 – May 9, 2008 · Past); Myogen Inc (Director · May 4, 2006 – Nov 13, 2006 · Past); Dynavax Technologies Corporation (Director · Feb 23, 2006 – May 28, 2020 · Past)
Director · Oct 9, 2013 – Feb 18, 2014 · Past
David Stump
Other companies: Regenxbio Inc. (Independent Board Member · Since at least Oct 14, 2015); Portola Pharmaceuticals Inc (Director · Sep 24, 2015 – Jul 2, 2020 · Past); Dendreon Corp (Director · Jun 2, 2010 – Jan 3, 2014 · Past); Sunesis Pharmaceuticals Inc (Director · Jun 18, 2009 – Jun 30, 2020 · Past); Human Genome Sciences Inc (Exec. Vice President · Mar 10, 2009 – Jul 30, 2012 · Past)
Director · Since at least Oct 9, 2013
Edward Hurwitz
Other companies: Dyne Therapeutics, Inc. (Director · Since at least Jul 31, 2020); Turmeric Acquisition Corp (Chief Financial Officer · Oct 15, 2020 – Oct 15, 2020 · Past); Tvardi Therapeutics, Inc. (Director · Jan 30, 2014 – Feb 5, 2014 · Past); Sunesis Pharmaceuticals Inc (Director · Apr 3, 2009 – Jun 28, 2013 · Past)
Director · Since at least Oct 9, 2013
Scott Thomas Jackson
Other companies: Mural Oncology plc (Director · Since at least Oct 31, 2023); Spero Therapeutics, Inc. (Director · Since at least Apr 16, 2020); Crescent Biopharma, Inc. (Director · Nov 27, 2018 – May 1, 2024 · Past); Celator Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 14, 2013 – Jul 12, 2016 · Past)
Director · Since at least Jan 24, 2017
Eran Nadav
Other companies: Trevi Therapeutics, Inc. (Director · May 7, 2019 – May 7, 2019 · Past); Collegium Pharmaceutical, Inc. (Director · May 6, 2015 – Jun 9, 2016 · Past); Ultragenyx Pharmaceutical Inc. (Director · Jan 30, 2014 – Jul 10, 2014 · Past)
Director · Oct 9, 2013 – Oct 9, 2013 · Past
Jon Marc Wigginton
Other companies: Sutro Biopharma, Inc. (Director · Since at least Nov 30, 2020); Checkmate Pharmaceuticals Inc (Director · Jan 30, 2022 – May 31, 2022 · Past); Cullinan Therapeutics, Inc. (Chief Medical Officer · Jan 7, 2021 – Jan 7, 2021 · Past)
Sr VP, Clinical Dev. & CMO · Oct 9, 2013 – Feb 20, 2020 · Past
Kenneth Galbraith
Other companies: Theravance Biopharma, Inc. (Chair & CEO · Since at least Nov 5, 2026); Zymeworks Inc. (Chair & CEO · Since at least Jan 15, 2022); Celator Pharmaceuticals Inc (Director · Jan 14, 2013 – Jun 3, 2013 · Past)
Director · Oct 9, 2013 – May 13, 2021 · Past
Meenu Chhabra
Other companies: Apexigen Inc. (Director · Jul 29, 2022 – Aug 23, 2023 · Past); GRI Bio, Inc. (Director · Feb 23, 2022 – Feb 23, 2022 · Past); Kineta Inc. (President and CEO, Director · Feb 10, 2016 – Mar 2, 2020 · Past)
Director · Since at least Jan 3, 2023
Atul Saran
Other companies: Emergent BioSolutions Inc. (EVP, Chief Strat & Dev Officer · Jul 20, 2017 – Feb 28, 2023 · Past); Xencor, Inc. (Director · Dec 2, 2013 – Dec 6, 2013 · Past)
SVP & General Counsel · Jun 5, 2014 – Apr 28, 2017 · Past
Paulo F Costa
Other companies: CorMedix Inc. (Director · Sep 15, 2020 – May 17, 2023 · Past); Amylin Pharmaceuticals LLC (Director · Jun 9, 2009 – Aug 8, 2012 · Past)
Director · Oct 9, 2013 – May 13, 2021 · Past
All 26 people
PersonSeat
Federica F O'Brien
Other companies: TELA Bio, Inc. (Director · Since at least Nov 7, 2019)
Director · Since at least Feb 10, 2021
Karen Ferrante
Other companies: Cogent Biosciences, Inc. (Director · Since at least Oct 1, 2020)
Director · Since at least May 13, 2021
Scott Koenig
Other companies: Crescent Biopharma, Inc. (Director · Mar 9, 2017 – May 1, 2024 · Past)
Director · Since at least Oct 9, 2013
William Heiden
Other companies: Atara Biotherapeutics, Inc. (Director · Since at least Jun 23, 2022)
Director · Since at least May 23, 2022
Beth Ann SmithVP, Controller & Treasurer · Since at least Jan 2, 2025
Eric RisserPresident and CEO, Director · Since at least Oct 9, 2013
Ezio BonviniSr VP, Research & CSO · Since at least Feb 20, 2020
James KarrelsSVP and CFO · Since at least Jun 15, 2022
Jay Philip SiegelDirector · Since at least Nov 13, 2017
Jeffrey Stuart PetersSenior VP, GC, and Secretary · Since at least Dec 31, 2017
Jim KarrelsSenior Vice President, CFO · Since at least Nov 3, 2026
Lynn CilinskiVP, Controller and Treasurer · Oct 9, 2013 – Feb 15, 2024 · Past
Margaret LiuDirector · Since at least Jan 3, 2023
Meenu Chhabra KarsonDirector · Since at least Nov 5, 2026
Stephen L EckChief Medical Officer · Feb 15, 2023 – Feb 15, 2025 · Past
Thomas SpitznagelSr VP, Technical Ops · Since at least Feb 8, 2024

Open People

Log in to ask 6ix AI your own questions about MacroGenics, Inc.